Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GNPS Comparable plasma lipid changes in patients with high-grade cervical intraepithelial neoplasia and patients with cervical cancer

ABSTRACT: Comparable plasma lipid changes in patients with high-grade cervical intraepithelial neoplasia and patients with cervical cancer

INSTRUMENT(S): ACQUITY UPLC H-Class, TripleTOF 5600

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Geum-Sook Hwang

PROVIDER: MSV000086351 | GNPS | Thu Oct 22 00:02:00 BST 2020

REPOSITORIES: GNPS

ACCESS DATA

Json Xml

Publications

Comparable Plasma Lipid Changes in Patients with High-Grade Cervical Intraepithelial Neoplasia and Patients with Cervical Cancer.

Nam Miso M Seo Sang-Soo SS Jung Sunhee S Jang Seo Young SY Lee Jueun J Kwon Minji M Khan Imran I Ryu Do Hyun DH Kim Mi Kyung MK Hwang Geum-Sook GS

Journal of proteome research 20201126 1

Cervical cancer is the fourth most prevalent cancer among women worldwide and usually develops from cervical intraepithelial neoplasia (CIN). In the present study, we compared alterations in lipids associated with high-grade CIN and cervical cancer with those associated with a normal status and low-grade CIN by performing global lipid profiling on plasma (66 healthy controls and 55 patients with CIN1, 44 with CIN2/3, and 60 with cervical cancer) using ultraperformance liquid chromatography/quadr ...[more]

PMID: 33241689

Similar Datasets

Genetic changes in high-grades serous ovarian cancer

Project description:Comparative genomic hybridization analysis on advanced stage high-grade serous ovarian cancer. CGH was performed on 42 DNA isolated from microdissected advanced stage high-grade serous ovarian cancer.

2009-10-02 | E-GEOD-18154 | biostudies-arrayexpress

MicroRNA profiling of plasma exosomes of ESCC patients

Project description:MiRNA arrays were performed for the plasma exosomes of ESCC patients before treatment. The tumor regression grade of the primary tumor (TRG-PT) was used to evaluate the therapeutic effect of chemoradiotherapy (CRT). Patients classified as Grade 3 were considered sensitive to CRT (n=4), while those classified as Grade 0 or 1a were considered resistant to CRT (n=4).

2022-02-03 | GSE195974 | GEO

Identification of changes in gene expression between cancer states taken from high grade serous ovarian cancer patients [RNA-Seq]

Project description:Identification of changes in gene expression between cancer states taken from high grade serous ovarian cancer patients [RNA-Seq]

| PRJNA475526 | ENA

Genetic changes in high-grades serous ovarian cancer

Project description:Comparative genomic hybridization analysis on advanced stage high-grade serous ovarian cancer.

2009-10-02 | GSE18154 | GEO

Identification of gene signature in microdissected omental adipose tissue from high grade serous ovarian cancer patients

Project description:Advanced ovarian cancer usually spreads to the omentum. However, the omental cell-derived molecular determinants modulating its progression have not been thoroughly characterized. Transcriptome profiling was performed on microdissected omental adipose tissue obtained from patients with benign gynecologic diseases and on cancer-associated omental tissue obtained from patients with advanced-stage, high grade serous ovarian cancer.

2019-09-20 | GSE120196 | GEO

Identification of changes in gene expression between cancer states taken from high grade serous ovarian cancer patients [RNA-Seq]

Project description:In order to identify specific events that are causatively involved in the metastatic process, we analyzed matched samples from 3 high grade serous ovarian cancer patients by RNA-seq. For each patient we examined samples representing the three cancer states: 1) primary tumor; 2) omentum metastasis (solid metastasis); 3) effusion metastasis. We identified genes differentially expressed between the various states. One of the genes found to be expressed in the primary tumor but not in the omentum or effusion metastasis is FOXL2, a transcription factor known to play a role in ovarian development and function. This change was successfully validated by RT-PCR in both the patients' samples as well as in a set of 27 independent patient samples representing the three cancer states. Knock-down of FOXL2 in patient-derived immortal fallopian tube cells lead to increased proliferation and survival. RNA-seq of the immortal fallopian tube cells after FOXL2 knock-down revealed a pro-metastatic gene expression signature. Our results suggest that FOXL2 is an important tumor suppressor and an inhibitor of ovarian cancer progression.

2021-06-01 | GSE115573 | GEO

Genome-wide analysis of mRNA expression alterations in Stage III-IV high-grade serous ovarian cancer patients exhibiting clinically defined differences in ascites volume (high volume ascites versus low volume ascites)

Project description:Microarrays were used to examine gene expression changes in the surgical resections of high-grade serous ovarian cancer patients exhibiting clinically distinct levels of ascites volume. The present studies primary aim was to determine if there is a molecular gene expression difference between the patients presenting at time of surgery when high volumes ascites cases were compared to those with low volume ascites. The secondary aim was to determine what relevance this difference, if found, has to previously discovered molecular sub-types of high grade serous ovarian cancer. Total RNA obtained from snap-frozen stage III-IV high-grade serous ovarian cancer patients presenting with low volume (<=200 cc) or high volume (>=1000 cc) ascites volume.

2014-10-01 | E-GEOD-51831 | biostudies-arrayexpress

Biomarkers in older ovarian cancer patients

Project description:Identification and validation of potential prognostic biomarkers in older ovarian cancer patients with high-grade serous adenocarcinoma (HGSC)

2020-03-01 | GSE126308 | GEO

RNA-seq analysis of liver cancer patients' plasma

Project description:RNA-seq analysis of liver cancer patients' plasma

| PRJNA598835 | ENA

Plasma circulating MiRNAs: a new potential biomarker for prostate cancer diagnosis.

Project description:Purpose: PCa is the second most commonly diagnosed malignancy in men. PCa Diagnosis are based on biopsy sampling that is an invasive, expensive procedure and does not accurately represent multifocal disease. It is desirable to have an easily accessible, minimally invasive way to accurately determine the molecular signature of patient’s tumor that can aid in diagnosis and risk stratification. Methods:we enrolled a total of 70 patients underwent 12-core transrectal ultrasound (TRUS) biopsy of which 48% had cancer in the diagnosis. The mean age at diagnosis was 67.15 (IR 55/75), the mean PSA (ng/ml) at diagnosis was 7.8 (IR 4.1/13.4) and the mean TRUS Volume (ml) was 53.5 (IR 29/86). The cancer biopsy presented 73.1% of positive core. Among all cancer patients, 57% showed a High grade of cancer status (Grade 3). Controls are patients with Benign Prostate Hyperplasia (BPH). MicroRNA-expression profiling (NGS analysis) was performed to identify tumor-related microRNAs (miRs) and determine their association with clinicopathological characteristics. Results: The expression of miRs -4732-3p, let7a, 26b-5p, 98-5p, 30c-5p and 21-5p may identified Prostate Cancer in plasma samples. Higher expression of mir-4732-3p is associated with a high grade tumor Conclusions: miRs signature discriminate Prostate cancer in plasma better to PSA values and is associated with high grade tumor status

2020-11-01 | GSE118038 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data